Intravascular ultrasound tech developer Evident Vascular exits stealth mode with $35M Series A
Summary
It enables both superior imaging and streamlined workflows.The companys launch came with the $35 million in funding from Vensana Capital. Managing Partner Dr. Justin Klein said in a news release that the impetus to launch Evident came from Vensanas experience in the vascular space. According to Vensana Principal Cynthia Yee, the space has seen significant advances in peripheral vascular disease treatments. However, she sees a lag in the diagnostic tools needed to accurately and appropriately guide therapy delivery.We see a tremendous opportunity to create a next-generation IVUS platform that addresses the needs of vascular interventionalists, and we are excited to be partnering with an outstanding team to launch Evident Vascular, Yee said.According to Howard Rosen, Evident Vascular CEO and co-founder, Shortcomings in image quality, interpretation and workflow have stunted IVUS. However, he believes in its clinical benefit despite the minimal innovation to address these limitations.Along with my co-founders, Chief Technology Officer Patrick Phillips and Chief Product Officer Danielo Piazza, our team is pioneering the future of intravascular imaging with a platform optimized for peripheral vascular procedures that will enable improved image interpretation guidance, and ease of use enhancements throughout the clinical workflow, Rosen said.
Funding
Review available funding amount, funding date, investors, and linked company information related to Intravascular ultrasound tech developer Evident Vascular exits stealth mode with $35M Series A in the interactive ISVWorld profile.